1.Update of PDE5 inhibitors for the treatment of ischemia-reperfusion.
National Journal of Andrology 2011;17(9):842-846
Phosphodiesterase type 5 (PDE5) inhibitors are used most commonly in the treatment of penile erectile dysfunction (ED). Recent studies show that PDE5 inhibitors are ideal drugs for treating ischemia-reperfusion injury. This review focuses on the results of basic and clinical researches on PDE5 inhibitors for the treatment of ischemia-reperfusion injury and provides some theoretical evidence for clinical options of the drugs.
Erectile Dysfunction
;
drug therapy
;
Humans
;
Male
;
Phosphodiesterase 5 Inhibitors
;
therapeutic use
;
Phosphodiesterase Inhibitors
;
therapeutic use
;
Reperfusion Injury
;
drug therapy
2.Tadalafil for erectile dysfunction: efficacy evaluation.
National Journal of Andrology 2009;15(4):379-383
A new type of phosphodiesterase 5 inhibitor, Tadalafil, has been used clinically to treat erectile dysfunction (ED). In this review, we analyzed the recent findings from the clinical trials on tadalafil in ED treatment. All data showed that oral tadalafil was an effective and well-tolerated therapeutic for ED, with many potential pharmacological actions. All this may help to give full play to the clinical value of tadalafil.
Carbolines
;
therapeutic use
;
Erectile Dysfunction
;
drug therapy
;
Humans
;
Male
;
Phosphodiesterase Inhibitors
;
therapeutic use
;
Tadalafil
3.Efficacy and safety of vardenafil in difficult-to-treat erectile dysfunction men.
National Journal of Andrology 2006;12(4):377-380
This paper reviewed the efficacy and safety of vardenafil, a highly selective phosphodiesterase type 5 (PDE 5) inhibitor, in men with erectile dysfunction who were difficult to treat. Several large-scale studies indicated vardenafil was effective and safe in the treatment of these difficult-to-treat ED patients, including ED with depression or diabetes, ED after radical retropubic prostatectomy, ED caused by spinal cord injury, and sildenafil nonresponders. Vardenafil provides a rational treatment alternative.
Erectile Dysfunction
;
drug therapy
;
Humans
;
Imidazoles
;
therapeutic use
;
Male
;
Middle Aged
;
Phosphodiesterase Inhibitors
;
therapeutic use
;
Piperazines
;
therapeutic use
;
Sulfones
;
therapeutic use
;
Treatment Outcome
;
Triazines
;
therapeutic use
;
Vardenafil Dihydrochloride
4.Influence of erectile dysfunction course on its progress and efficacy of treatment with phosphodiesterase type 5 inhibitors.
De-Feng LIU ; Hui JIANG ; Kai HONG ; Lian-Ming ZHAO ; Wen-Hao TANG ; Lu-Lin MA
Chinese Medical Journal 2010;123(22):3258-3261
BACKGROUNDErectile dysfunction (ED) is a common impairment among older men, and the prevalence rates increase sharply after age of 60 years. Most studies have focused on the prevalence rate or dangerous factors. The aim of this study was to investigate the basic epidemiologic data about ED patients with different ED courses. The purpose of this research was to understand the therapeutic effect of phosphodiesterase type 5 inhibitor (PDE5-I) and see how and why the ED course impact the progress of ED and the therapeutic effect of PDE5-I treatment.
METHODSFrom June 2008 to June 2009, 4252 questionnaires (Quality of Erection Questionnaire, QEQ) were gathered from 46 centers by urology or andrology doctors all around China. Patients with ED (age ≥ 20 years) filled in first half of the questionnaires when they came for the first time, and then completed the second half 4 weeks after PDE5-I therapy.
RESULTSED courses of most patients were less than 5 years (< 5 years, 74.0%; 5 - 10 years 20.8%; > 10 years, 5.2%). As ED course increasing, the incidence of the risk factors of ED, such as smoking, drinking, hypertension, diabetes, heart disease and hyperlipidemia also increase (P ≤ 0.01). PDE5-I was effective in improving the quality of sexual activities (P ≤ 0.01). Administration of PDE5-I improves satisfaction, enjoyment and frequency of sexual activities. The longer the ED course, the worse the therapeutic effect (< 5 years, 96.1%; 5 - 10 years, 94.9%; > 10 years, 89.0%) (P ≤ 0.01).
CONCLUSIONSThe ED course greatly affected the therapeutic effect of PDE5-1, the patients with ED should consult doctor at early stage of the disease. Administration of PDE5-I effectively improves the penile erection and the quality of sexual life of the patients hence should be considered as first-line medicine in the treatment of ED.
Adult ; Erectile Dysfunction ; drug therapy ; epidemiology ; physiopathology ; Humans ; Male ; Phosphodiesterase 5 Inhibitors ; therapeutic use ; Surveys and Questionnaires
5.Advances in the studies of refractory erectile dysfunction.
National Journal of Andrology 2013;19(1):82-85
Erectile dysfunction (ED) is a common problem, for which PDE5 inhibitors (PDE5I) represent the first line therapy at present and have a success rate of approximately 80%. Refractory ED, which refers to ED in some patients with chronic diseases such as diabetes mellitus and cardiovascular diseases or in those treated by radical prostatectomy, receives little benefit from PDE5I alone. Apart from the NO-cGMP pathway, the processes of erection and ED involve several signaling pathways, such as RhoA/Rho kinase, H2S, CO, etc. The complicated signaling network contributes to the pathogenesis of refractory ED. PDE5I-based alternative therapy and combined therapy may increase the success rate of its treatment. This article outlines the advances in the studies of refractory ED that fails to respond to PDE5I.
Erectile Dysfunction
;
drug therapy
;
Humans
;
Male
;
Phosphodiesterase 5 Inhibitors
;
therapeutic use
6.Long-term administration of low-dose phosphodiesterase type 5 inhibitors for erectile dysfunction: an update.
National Journal of Andrology 2013;19(3):195-198
Erectile dysfunction (ED) is a common disorder that affects the quality of life of both men and their partners. The phosphodiesterase type 5 inhibitor is the first-line drug for ED. Recent researches found that long-term administration of low-dose phosphodiesterase type 5 inhibitors to be a safe and effective therapy for ED, as well as for couples who may prefer more convenience and spontaneity in their sexual activities. Besides, it provides a new therapeutic option for refractory ED. Its action mechanism mainly involves the improvement of the endothelial function of penile vessels and/or maintenance of the function and number of smooth muscle cells. However, whether this therapy can maintain the improved erection function after drug withdrawal needs further studies.
Erectile Dysfunction
;
drug therapy
;
Humans
;
Male
;
Phosphodiesterase 5 Inhibitors
;
administration & dosage
;
therapeutic use
;
Treatment Outcome
7.Efficacy and safety of phosphodiesterase inhibitors for erectile dysfunction in diabetic men: A meta analysis.
Qing LIU ; Jian CAI ; Li-zhang LIN ; Cheng-di LI ; Zhi-gang WU
National Journal of Andrology 2015;21(5):447-457
OBJECTIVETo evaluate the clinical efficacy and safety of phosphodiesterase 5 (PDE-5) inhibitors for erectile dysfunction (ED) in patients with diabetes mellitus and provide some evidence for the clinical treatment of the disease.
METHODSWe searched MedMed, EMbase, Cochrane Library, CNKI, Wan Fang Data, VIP and ZADL for randomized controlled trials on PDE-5 inhibitors for ED in diabetic men and evaluated the methodology of the included trials with the Jadad scale. We used the erectile function domain in the IIEF (IIEF-EF), IIEF questions (IIEF-Q) 3 and 4, SEP-2 and -3, and Global Assessment Questions (GAQ) as the main evaluation indexes and employed the Review Manager 5. 1. 0 software for meta analysis.
RESULTSA total of 13 studies were included, which were all high quality trials with Jadad score > 3. The IIEF-EF scores in 10 of the included studies were subjected to meta analysis using the random-effect model (REM), with a weighted mean difference (WMD) of 5.64 (95% CI 4.41 - 6.83, P < 0.001). The fixed-effect model (FEM) analysis of the IIEF-Q scores in 6 of the studies showed the WMD to be 0.96 (95% CI 0.83 -1.08, P < 0.001) for IIEF-Q3 and 1.11 (95% CI 0.98 - 1.25, P < 0.001) for IIEF-Q4. FEM analysis of the SEP-2 scores showed WMD = 17.67 (95% CI 12. 38 - 22. 97, P < 0.001) in 2 of the studies, and that of the SEP-3 scores WMD = 23.64 (95% CI 17. 49 - 29.79, P < 0.001) in 5 of the studies. The GAQ scores in 11 of the studies were subjected to REM analysis, with OR = 6. 20 and 95% CI 3.65 - 10.52 (P < 0.001). REM analysis was performed on the adverse reactions in 11 of the studies, with OR = 7.43 and 95% CI 4.11 - 13.44 (P < 0.001).
CONCLUSIONPDE-5 inhibitors can effectively and safely improve erectile function in patients with diabetes mellitus.
Diabetes Mellitus ; Erectile Dysfunction ; drug therapy ; Gangliosides ; Humans ; Male ; Penile Erection ; Phosphodiesterase 5 Inhibitors ; therapeutic use
8.Efficacy and safety of tadalafil for erectile dysfunction: an updated review.
National Journal of Andrology 2009;15(10):956-959
As a long-acting phosphodiesterase type 5 (PDE5) inhibitor, tadalafil is administered orally as the first line therapy for erectile dysfunction (ED). Its efficacy and safety have been confirmed by many clinical studies in the treatment of ED in general patients, elderly patients and those with diabetes mellitus or spinal cord injury or after prostate cancer surgery. With its prolonged action of 36 hours, tadalafil can not only increase the self-esteem of ED men but also improve the quality of life of both the patients and their partners.
Carbolines
;
administration & dosage
;
therapeutic use
;
Erectile Dysfunction
;
drug therapy
;
Humans
;
Male
;
Phosphodiesterase Inhibitors
;
administration & dosage
;
therapeutic use
;
Tadalafil
9.Tadalafil for erectile dysfunction associated with cardiovascular diseases.
National Journal of Andrology 2013;19(9):860-863
Erectile dysfunction (ED) seriously affects the quality of men's sexual life. Recent studies have shown that ED is closely related with cardiovascular diseases, and they have many similar pathogenic mechanisms and common risk factors. A great many researches have confirmed the clinical efficacy of tadalafil in the treatment of ED associated with cardiovascular diseases. With its prolonged action of 36 hours, tadalafil can not only increase the self-confidence of ED males but also improve the quality of life of both the patients and their partners.
Carbolines
;
therapeutic use
;
Cardiovascular Diseases
;
complications
;
drug therapy
;
Erectile Dysfunction
;
complications
;
drug therapy
;
Humans
;
Male
;
Phosphodiesterase Inhibitors
;
therapeutic use
;
Tadalafil
10.Tadalafil and patients preference in the treatment of erectile dysfunction.
National Journal of Andrology 2006;12(12):1145-1148
ED treatment has changed fundamentally since phosphodiesterase type 5 inhibitor (PDE5-I) came into clinical use. There are three kinds of PDE5-I available at present, Sildenafil, Vardenafil and Tadalafil. Tadalafil distinguishes from the other two by its uniquely long half-life, which lasts 17.5h, which a pharmacodynamic duration of 36h and not influenced by food and alcohol. Thus it may enable ED patients to accomplish a spontaneous intercourse without the need of prior preparation without, which can boost their confidence and self-esteem and, the most important, improve the relationship with their partner. To know patient preference counts quite a lot in optimizing the medication ED treatment.
Carbolines
;
therapeutic use
;
Erectile Dysfunction
;
drug therapy
;
psychology
;
Humans
;
Male
;
Patient Satisfaction
;
Phosphodiesterase Inhibitors
;
therapeutic use
;
Psychotherapy
;
Tadalafil